EU/3/20/2345: Orphan designation for the treatment of primary IgA nephropathy

Sparsentan

Overview

On 19 October 2020, orphan designation EU/3/20/2345 was granted by the European Commission to Travere Therapeutics Ireland Limited, Ireland, for sparsentan for the treatment of primary IgA nephropathy.

Key facts

Active substance
Sparsentan
Intended use
Treatment of primary IgA nephropathy
Orphan designation status
Positive
EU designation number
EU/3/20/2345
Date of designation
19/10/2020
Sponsor

Vifor France S.A. 
Tour Franklin La Defense 8 
100-101 Terrasse Boieldieu 
92042 Paris La Defense Cedex 
France
E-mail: contact-fr@viforpharma.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
December 2021The sponsorship was transferred to Vifor France S.A., France.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating